lymphoid cells

[ACS Nano] Investigators described a strategy that utilizes pretargeting and glycochemistry to bioengineer β cells in situ to induce β-cell-specific tolerance.

[Technology Networrks] The California Institute for Regenerative Medicine governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

[Nanomedicine-Nanotechnology Biology and Medicine] Multifunctional bilayered dermal patches with antibacterial, antioxidant and anti-inflammatory properties were developed and compared for performance. Soluble eggshell membrane protein improved migration of human adult dermal fibroblasts, suggesting its contribution to wound healing.

[CRISPR Therapeutics] CRISPR Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy designation to CTX110™, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.

[Proceedings of the National Academy of Sciences of the United States of America] The authors reported that RORC2 was a key host cofactor for HIV replication in Th17 cells. They found that specific inhibitors that bound to the RORC2 ligand-binding domain reduced HIV replication in CD4+ T cells.

[Nature Communications] Investigators reported that intranasal vaccinations with adenovirus 5 and 19a vectored vaccines following a systemic plasmid DNA or mRNA priming resulted in systemic and mucosal immunity in mice.